{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:10:26Z","timestamp":1760029826499,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jemermed.2018.04.031","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T17:49:37Z","timestamp":1526752177000},"page":"347-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department"],"prefix":"10.1016","volume":"55","author":[{"given":"John P.","family":"Haran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Volturo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jemermed.2018.04.031_bib1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2018.04.031_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.rmed.2011.11.017","article-title":"Guideline adherence and macrolides reduced mortality in outpatients with pneumonia","volume":"106","author":"Asadi","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.jemermed.2018.04.031_bib3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1553-2712.2012.01365.x","article-title":"Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia","volume":"19","author":"Jenkins","year":"2012","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.jemermed.2018.04.031_bib4","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1164\/rccm.201504-0701ED","article-title":"Macrolide-resistant pneumococcus in community-acquired pneumonia. Is there still a role for macrolide therapy?","volume":"191","author":"Niederman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"year":"2015","series-title":"State of the World\u2019s Antibiotics, 2015","author":"Center for Disease Dynamics, Economics and Policy","key":"10.1016\/j.jemermed.2018.04.031_bib5"},{"key":"10.1016\/j.jemermed.2018.04.031_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/00325481.2016.1185375","article-title":"Where in the world? The role of geography in antibiotic resistance and the potential impact in pulmonary infections","volume":"128","author":"Tillotson","year":"2016","journal-title":"Postgrad Med"},{"author":"The Review on Antimicrobial Resistance","key":"10.1016\/j.jemermed.2018.04.031_bib7"},{"key":"10.1016\/j.jemermed.2018.04.031_bib8","unstructured":"Center for Disease Dynamics, Economics and Policy. Macrolide-resistant Streptococcus pneumoniae. Available at: www.cddep.org."},{"key":"10.1016\/j.jemermed.2018.04.031_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2010.03.2130","article-title":"Burden of community-acquired pneumonia in North American adults","volume":"122","author":"File","year":"2010","journal-title":"Postgrad Med"},{"year":"2016","series-title":"Antibiotic susceptability of Streptococcus pneumoniae in the USA in 2014","author":"Keedy","key":"10.1016\/j.jemermed.2018.04.031_bib10"},{"year":"2014","series-title":"National prescription audit","author":"IMS Health","key":"10.1016\/j.jemermed.2018.04.031_bib11"},{"year":"2015","series-title":"National disease and therapeutic index","author":"IMS Health","key":"10.1016\/j.jemermed.2018.04.031_bib12"},{"key":"10.1016\/j.jemermed.2018.04.031_bib13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae","volume":"35","author":"Lonks","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2018.04.031_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-0711-7-1","article-title":"Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4","volume":"7","author":"Jenkins","year":"2008","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jemermed.2018.04.031_bib15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3201\/eid1508.081187","article-title":"Increase in pneumococcus macrolide resistance, United States","volume":"15","author":"Jenkins","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jemermed.2018.04.031_bib16","first-page":"247","article-title":"Progressive and nonresolving pneumonia","volume":"11","author":"Low","year":"2005","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jemermed.2018.04.031_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10096-006-0113-3","article-title":"Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia","volume":"25","author":"Genne","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl","key":"10.1016\/j.jemermed.2018.04.031_bib18","first-page":"S63","article-title":"Patterns of antibiotic treatment failure in pediatric community-acquired bacterial pneumonia in the United States [abstract]","volume":"22","author":"Lopatkin","year":"2016","journal-title":"J Manage Care Spec Pharm"},{"key":"10.1016\/j.jemermed.2018.04.031_bib19","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkn073","article-title":"Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance","volume":"61","author":"Asche","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jemermed.2018.04.031_bib20","doi-asserted-by":"crossref","first-page":"e0119528","DOI":"10.1371\/journal.pone.0119528","article-title":"Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia","volume":"10","author":"Falcone","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jemermed.2018.04.031_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2334-14-61","article-title":"Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department","volume":"14","author":"Micek","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jemermed.2018.04.031_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2047-2994-3-16","article-title":"Attributable healthcare utilization and cost of pneumonia due to drug-resistant streptococcus pneumonia: a cost analysis","volume":"3","author":"Reynolds","year":"2014","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jemermed.2018.04.031_bib23","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1164\/rccm.200603-350OC","article-title":"A worldwide perspective of atypical pathogens in community-acquired pneumonia","volume":"175","author":"Arnold","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jemermed.2018.04.031_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5582\/bst.2016.01021","article-title":"Atypical pathogen infection in community-acquired pneumonia","volume":"10","author":"Yu","year":"2016","journal-title":"Biosci Trends"},{"key":"10.1016\/j.jemermed.2018.04.031_bib25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.01806-13","article-title":"More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia","volume":"58","author":"Zhou","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jemermed.2018.04.031_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1086\/505871","article-title":"Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management","volume":"43","author":"Daneman","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2018.04.031_bib27","first-page":"876","article-title":"Electronic quality measurement predicts outcomes in community acquired pneumonia","volume":"2012","author":"Sims","year":"2012","journal-title":"AMIA Annu Symp Proc"},{"key":"10.1016\/j.jemermed.2018.04.031_bib28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/mdr.2014.0064","article-title":"Poor compliance with community-acquired pneumonia antibiotic guidelines in a large Australian private hospital emergency department","volume":"20","author":"Robinson","year":"2014","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jemermed.2018.04.031_bib29","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/civ076","article-title":"US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011","volume":"60","author":"Hicks","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6 Suppl 1","key":"10.1016\/j.jemermed.2018.04.031_bib30","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.jped.2015.08.002","article-title":"Use of macrolides in lung diseases: recent literature controversies","volume":"91","author":"Silva Filho","year":"2015","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.jemermed.2018.04.031_bib31","first-page":"CD007716","article-title":"Macrolides for diffuse panbronchiolitis","volume":"2","author":"Yang","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jemermed.2018.04.031_bib32","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1128\/AAC.00652-15","article-title":"Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections","volume":"59","author":"Schroeck","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jemermed.2018.04.031_bib33","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/324527","article-title":"Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia","volume":"34","author":"Lynch","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2018.04.031_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/380126","article-title":"The clinical significance of macrolide-resistant Streptococcus pneumoniae: it\u2019s all relative","volume":"38","author":"Nuermberger","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2018.04.031_bib35","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/jac\/dki060","article-title":"Meta-analysis of bacterial resistance to macrolides","volume":"55","author":"Halpern","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jemermed.2018.04.031_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.48.1482","article-title":"Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection","volume":"48","author":"Yanagihara","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.jemermed.2018.04.031_bib37","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1164\/rccm.201502-0212OC","article-title":"The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia","volume":"191","author":"Cilloniz","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jemermed.2018.04.031_bib38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1179\/joc.2007.19.5.536","article-title":"A case series of macrolide treatment failures in community acquired pneumonia","volume":"19","author":"Iannini","year":"2007","journal-title":"J Chemother"},{"key":"10.1016\/j.jemermed.2018.04.031_bib39","doi-asserted-by":"crossref","first-page":"584262","DOI":"10.1155\/2012\/584262","article-title":"Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics","volume":"2012","author":"Steel","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jemermed.2018.04.031_bib40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.112.200733","article-title":"A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-\u03baB inhibition","volume":"345","author":"Kobayashi","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jemermed.2018.04.031_bib41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.289.7.885","article-title":"Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use","volume":"289","author":"Neuhauser","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2018.04.031_bib42","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1128\/JCM.01284-07","article-title":"Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004","volume":"45","author":"Lockhart","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jemermed.2018.04.031_bib43","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3201\/eid0912.03-168","article-title":"Factors influencing fluoroquinolone resistance","volume":"9","author":"Sahm","year":"2003","journal-title":"Emerg Infect Dis"},{"author":"Center for Disease Dynamics, Economics and Policy website","key":"10.1016\/j.jemermed.2018.04.031_bib44"},{"key":"10.1016\/j.jemermed.2018.04.031_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0011-393X(04)80047-X","article-title":"Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumonia","volume":"65","author":"Liu","year":"2004","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jemermed.2018.04.031_bib46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/00151829-200605060-00009","article-title":"A review of new fluoroquinolones : focus on their use in respiratory tract infections","volume":"5","author":"Zhanel","year":"2006","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.jemermed.2018.04.031_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2710.2009.01073.x","article-title":"Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia","volume":"35","author":"Mokabberi","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jemermed.2018.04.031_bib48","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1086\/586749","article-title":"The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy","volume":"46","author":"Charles","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2018.04.031_bib49","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1111\/j.1469-0691.2011.03759.x","article-title":"Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia","volume":"18","author":"Teh","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jemermed.2018.04.031_bib50","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dkm033","article-title":"Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance","volume":"59","author":"Martin","year":"2007","journal-title":"J Antimicrob Chemother"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467918303706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467918303706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:39:57Z","timestamp":1760027997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467918303706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0736467918303706"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2018.04.031","relation":{},"ISSN":["0736-4679"],"issn-type":[{"type":"print","value":"0736-4679"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2018.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}